Disease · MONDO_0018752
exercise-induced malignant hyperthermia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. exercise-induced malignant hyperthermia. Diseases, record MONDO_0018752. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018752
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs1
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here |
|---|---|---|---|---|---|---|---|
| DANTROLENE SODIUM | CHEMBL928 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 |
Source Drugs and targets
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| RYR1 | Ryanodine receptor 1 | 1 | Ryanodine receptor 1 antagonist | Phase 3 | https://conductscience.org/library/genes/6261 | Drugs and targets |
| RYR3 | Ryanodine receptor 3 | 1 | Ryanodine receptor 3 antagonist | Phase 3 | https://conductscience.org/library/genes/6263 | Drugs and targets |
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02513095 | Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) | Phase 2 | 34 | 2017-05-09 | Heat Stroke | DANTROLENE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03600376 | Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS | Phase 3 | 17 | 2021-04-26 | Exertional Heat Stroke | DANTROLENE SODIUM | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ryanodex vs Standard of Care Only (SOC): deaths from any cause | 1 of 17 | 0 of 17 | 34 | NCT02513095 | Trial comparisons |
| Ryanodex Plus Standard of Care vs Standard of Care: Number of Subjects Achieving Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 | 5 of 17 | 2 of 17 | 34 | NCT02513095 | Trial comparisons |
| Ryanodex vs Standard of Care Only (SOC): serious adverse events | 4 of 17 | 3 of 17 | 34 | NCT02513095 | Trial comparisons |
Ryanodex and Standard of Care vs Standard of Care Only (SOC): Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization] | 4 of 9 | 2 of 8 | 17 | NCT03600376 | Trial comparisons |
| Ryanodex and Standard of Care vs Standard of Care Only (SOC): deaths from any cause | 0 of 9 | 0 of 8 | 17 | NCT03600376 | Trial comparisons |
| Ryanodex and Standard of Care vs Standard of Care Only (SOC): serious adverse events | 1 of 9 | 2 of 8 | 17 | NCT03600376 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 33848093 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018752
GET https://conductscience.org/api/diseases/v1/MONDO_0018752/drugs